Demand for pharmaceuticals in emerging markets is forecast to grow by 13% – triple that of traditional Western markets – and will account for 40% of growth in the worldwide pharmaceutical market by 2020.

GSK has established a new business model of prioritising emerging economy investments in capacity and regulatory expertise to strengthen the company’s footprint in growth markets.


GSK chief executive Andrew Witty said: “These new strategic priorities will evolve GSK into a company that has a balanced group of healthcare businesses and a lower overall risk profile. They also point to a more disciplined allocation of capital across all our different business areas”.